20 Future Estonian HealthTech and MedTech Leaders

Nelson Advisors
3 hours ago
14 min read

The Estonian Health Technology and Medical Science Renaissance: A Comprehensive Analysis of Twenty Future Leaders

The emergence of Estonia as a preeminent global centre for health technology and medical engineering is a phenomenon predicated on the strategic synthesis of high-fidelity genomic data, a sophisticated digital identity infrastructure and a robust entrepreneurial ecosystem that prioritises clinical validation alongside technological scalability.

The transition from traditional reactive medical models, often characterised as "sick-care", toward a proactive, personalised, and predictive health economy is driven by a cohort of leaders who bridge the gap between academic rigour and commercial viability.

As the Estonian healthtech sector moves toward its "Vision 2035," which anticipates a high-density environment of science-based startups and a significant increase in healthy life years for the population, twenty specific individuals have surfaced as the architects of this transformation.

This report provides an analysis of these twenty future leaders, their technical contributions and the strategic implications of their work for the global healthcare landscape.

The Genomic Sovereignty and Pharma-cogenomic Integration

Estonia’s competitive advantage in medical technology is inextricably linked to the Institute of Genomics at the University of Tartu and the Estonian Biobank, which houses data for over 212,000 individuals. This repository is not merely a data archive but an active instrument for clinical intervention and precision medicine.

Lili Milani: The Vanguard of Biobank Translation

Professor Lili Milani, Head of the Estonian Biobank and Professor of Pharmacogenomics, represents the critical link between longitudinal genomic studies and frontline medical application. Her leadership is defined by the objective to "decode health, one genome at a time," moving beyond data collection toward actionable insights that influence drug response and disease prevention.

A seminal achievement under her direction was the 2024 launch of the MyGenome portal, a pioneering online platform that allows biobank participants to view their genetic risk assessments and traits directly. This shift toward patient-centric data ownership reflects a broader trend in Estonian digital society where individuals are active participants in their health management.

Milani’s academic work investigates the genetics of interindividual variation in drug response, specifically exploring how pharmacogenetics and epigenetics can mitigate adverse events and improve outcomes in psychiatric and cardiovascular conditions. Her research group's ability to pair over 2,300 whole genomes with national electronic health records allows for the identification of rare loss-of-function mutations and their phenotypic consequences. This methodology is fundamental to the "predictive and prescriptive" healthcare model envisioned for the next decade.

Triin Laisk: Deciphering the Molecular Basis of Reproductive Health

Professor Triin Laisk, Professor of Genomic Epidemiology at the University of Tartu, has fundamentally altered the discourse around women’s health through her research into the genetic mechanisms of reproductive disorders. Recognised with the University’s Research Award in 2025, Laisk’s team utilized large-scale genome-wide association studies (GWAS) to clarify the molecular underpinnings of conditions that have historically been treated based on symptomatic presentation rather than biological causation.

Laisk’s approach involves the simultaneous analysis of nearly fifty diagnoses related to female reproductive health, drawing on data from the Estonian Biobank and Finland’s FinnGen project. Her findings, published in journals such as Nature Medicine, enable a shift toward a more holistic and precise view of women’s health, offering insights into DNA repair, cell proliferation, and cell growth in relation to conditions like genital tract polyps and endometriosis. By uncovering these genetic triggers, Laisk provides the clinical foundation upon which future FemTech startups will develop targeted therapies and diagnostic tools.

Researcher	Key Focus Area	Methodology	Strategic Impact
Lili Milani	Pharmacogenomics	Whole-genome sequencing paired with EHR data.	Reducing adverse drug events and enabling precision medicine.
Triin Laisk	Reproductive Genetics	Large-scale GWAS and phenotypic mapping.	Shifting women’s health from symptomatic to causal diagnosis.
Kelli Lehto	Neuropsychiatric Genomics	Investigating adult ADHD through multi-omics.	Improving diagnostics and personalized treatment for mental health.
Maris Alver	Complex Traits	Genetic regulation of psychiatric and cardiometabolic traits.	Understanding the shared molecular pathways of chronic diseases.
Tõnu Esko	Data Integration	Cross-sectoral governance of health data systems.	Strengthening the bridge between research data and clinical implementation.

The Precision Oncology and Personalised Diagnostics Vanguard

Estonia's oncology sector is characterised by an advanced integration of genetic risk scoring and national data strategy, spearheaded by leaders who prioritise early detection and personalised prevention.

Peeter Padrik: Scaling Polygenic Risk Scores in Oncology

Dr. Peeter Padrik, an oncologist with over three decades of clinical experience, is the founder and CEO of Antegenes.Padrik’s leadership is rooted in the philosophy that the most effective cancer care is characterized by avoidance and early-stage detection. Antegenes utilises Polygenic Risk Score (PRS) technology to assess cumulative genetic risk for common cancers, providing individuals with clinical recommendations that dictate specific screening schedules.

Under Padrik’s guidance, the AnteBC breast cancer risk test has been integrated into several European healthcare systems.The impact of this technology is evidenced by the BRIGHT project, which demonstrated that PRS testing could identify over 41% of participants with an elevated risk of breast cancer, enabling them to start mammography screening earlier than the general population. Padrik’s work represents a successful transition from high-level genetic research to a scalable, CE-marked medical device that directly reduces cancer mortality rates.

Kadi-Liis Veiman: Orchestrating the Estonian Cancer Network

Kadi-Liis Veiman, the Head of the Estonian Cancer Network (ESTCAN), is a pivotal figure in the national strategy for cancer control. Recognised in 2025 for her contribution to society, Veiman leads a multidisciplinary team that has unified ten founding organisations, including medical, research, and patient groups—to function as a coherent system rather than fragmented entities.

Veiman’s leadership is essential for the implementation of the Estonian National Cancer Control Plan (2021–2030), which focuses on reducing cancer incidence and improving the quality of life for those diagnosed. Her role involves managing international research initiatives such as UNCAN-Connect, a €30 million project focused on secure, decentralized cancer data sharing across Europe.

By promoting the strategic integration of AI and data technologies, Veiman ensures that Estonia remains a leader in personalised medicine within oncology, facilitating a "borderless" approach to cancer research and innovation.

The Medtech Engineering and Material Science Revolution

The physical reality of healthcare, wound care, tissue engineering and diagnostics, is being reimagined by Estonian engineers who apply nanotechnology and material science to clinical challenges.

Olesja Bondarenko: Engineering Antimicrobial Synergy

Dr. Olesja Bondarenko, CEO and co-founder of Nanordica Medical, is a researcher whose work addresses the global crisis of antimicrobial resistance (AMR) through the lens of nanotechnology. Her leadership has transformed a decade of research at the National Institute of Chemical Physics and Biophysics into a medtech company that develops first-in-class wound care products.

Bondarenko’s innovation lies in the discovery of synergistic combinations of metal-based nanoparticles, such as copper oxide and silver, which can deactivate antibiotic-resistant bacteria up to six times more effectively than traditional methods. This is particularly critical for the treatment of chronic, hard-to-heal wounds, which Nanordica’s flagship product can heal twice as fast as current leading competitors. Her recognition as a runner-up for the 2025 European Prize for Women Innovators underscores the strategic value of her work in improving patient outcomes while tackling the broader societal challenge of AMR.

Märt-Erik Martens: The Industrialist of Nanofibers

Märt-Erik Martens, CEO and co-founder of Gelatex, is the architect of a technological shift in the production of nanofibers. Historically, nanofibers have been limited by high production costs and low scalability. Martens’s patented HaloSpin™ technology addresses these limitations by reducing production costs by up to 90%, enabling the industrial-scale use of nano0fibres in medical applications.

Under Martens’s leadership, Gelatex has focused on the biotech sector, where its nanofibers serve as scaffolds for scar-reducing wound care and more efficient drug discovery models. The 2024 Innovation Radar Prize in the Health Tech category highlights Martens’s success in moving from deep-tech engineering to a commercially viable platform that can disrupt the global market for biocompatible materials. His work is essential for the next generation of regenerative medicine and tissue engineering.

Digital Therapeutics and Accessibility Pioneers

Estonia’s digital-first approach to healthcare provides a unique advantage for leaders developing digital therapeutics and remote diagnostic platforms.

Liis Narusk: Revolutionising Remote Diagnostics

Liis Narusk, co-founder and CEO of Certific, has been a central figure in decoupling clinical diagnostics from physical healthcare facilities. Founded alongside Taavet Hinrikus, Certific utilized the urgency of the COVID-19 pandemic to launch the world’s first certified remote testing service, verifying identity and test results through video recording.

Following the pandemic, Narusk has transitioned Certific into a platform for broader chronic disease management, most notably through a partnership with PocDoc to tackle cardiovascular disease. This collaboration allows patients to remotely monitor blood pressure, BMI, and quantitative lipid levels through a unified digital interface. Narusk’s vision is to make healthcare "radically easier, cheaper, and more accessible" by empowering patients to perform medically certified tests—including swabs, blood, and urine tests—at home, thereby reducing the burden on primary care physicians.

Andres Mellik: Digital Support for Neurological and Speech Recovery

Andres Mellik, the founder of SpeakTX (and previously Cognuse), is a veteran of the digital health industry who has pioneered software solutions for critical disease management and rehabilitation. SpeakTX was developed to address the acute shortage of speech therapy professionals and the resulting long waiting lists for patients.

Mellik’s approach combines clinical expertise with engaging technology to create an interactive platform for speech therapy that is currently used in nearly 500 kindergartens, schools, and hospitals in Estonia. By offering personalized therapy plans and video consultation capabilities, Mellik ensures that individuals receive the support they need regardless of their geographic location. His leadership illustrates the power of "blended care," where digital tools enhance rather than replace the role of medical professionals.

Leader	Company	Sector	Primary Technological Contribution
Olesja Bondarenko	Nanordica Medical	Wound Care	Synergistic metal-based nanoparticles for AMR.
Märt-Erik Martens	Gelatex	Biotech Materials	HaloSpin™ technology for scalable nanofibers.
Liis Narusk	Certific	Remote Diagnostics	Video-verified remote testing for chronic diseases.
Andres Mellik	SpeakTX	Digital Therapeutics	AI-enabled speech and language therapy platform.
Katrina Laks	Migrevention	Digital Therapeutics	Evidence-based digital clinic for headache management.

The Ecosystem Architects and Strategic Visionaries

The Estonian healthtech sector’s growth is not accidental but the result of a deliberate construction of an ecosystem that supports founders from ideation to international expansion.

9 and 10. Erki Mölder and Siim Saare: The Gatekeepers of Health Innovation

As the founders of the Health Founders accelerator, Erki Mölder and Siim Saare have created the first vertical launchpad for healthtech in the Baltics. Mölder, with a background in healthcare management dating back to 1899, and Saare, a corporate CEO turned biohacker, provide early-stage startups with the clinical and regulatory mentorship required to survive the "world's most complex industry".

Their mission is to accelerate the growth of 100 health technology companies over the next decade, focusing on moving from "sick-care" models toward personalised, predictive interventions powered by AI and big data. By building an alliance of experts, including clinicians like David Yakobi and AI specialists like Shahab Anbarjafari, Mölder and Saare ensure that Estonian startups have a direct path to international markets and clinical validation.

Sandra Särav-Tammus: Crafting the Policy Sandbox

Sandra Särav-Tammus, Deputy Secretary General for Economy and Innovation, is a key figure in the governmental push for healthtech excellence. She has articulated a goal for Estonia to produce the highest number of healthtech unicorns per capita by 2035, a target she believes is achievable if the country addresses its workforce shortages and regulatory barriers.

Särav-Tammus advocates for a "co-creation" model where the state acts as a partner to startups, helping them navigate regulatory roadblocks and ensuring that Estonia remains a "living lab" for innovation. Her work is central to the national program "Estonia.ai," which aims to integrate artificial intelligence into all sectors of the economy by 2035, under the advisory leadership of entrepreneurs like Markus Villig and Taavi Madiberk.

Clinical Trial Innovation and Data Stewardship

The speed at which life-saving technologies reach the market is often determined by the efficiency of clinical trials and the strategic management of clinical data.

12 and 13. Anna-Liisa Parts and Jürgen Lorenz: Automating the Clinical Pipeline

Anna-Liisa Parts, co-founder and COO, and Jürgen Lorenz, CEO of Menken Trials, have developed a platform that addresses the chronic inefficiencies in clinical trial monitoring. With Parts’s background in clinical research at Tartu University Hospital and IQVIA, the team recognized that the industry was still hampered by paper-based processes and manual errors.

Their AI-enabled tool automates up to 60% of the tasks typically performed by clinical monitors, utilizing error detection algorithms to accelerate the review process. This innovation not only reduces the cost of clinical trials but also shortens the time required for drugs to reach the market, a critical factor for patient health globally. Under their leadership, Menken Trials has gained traction in US and UK markets, participating in prestigious accelerators like Tenity and CDL Estonia.

Kelli Lehto: Bridging Genetics and Psychology

Dr. Kelli Lehto, Associate Professor of Neuropsychiatric Genomics, leads European Research Council (ERC) funded projects that investigate the causes of complex mental health conditions like ADHD in adults. Her work is indicative of a broader trend in Estonian research that integrates genomic data with psychological and behavioural metrics to improve diagnostics.

Lehto’s research into the "Genetic risk and comorbid conditions in mental health" is essential for developing next-generation psychiatric interventions. By uncovering the shared genetic components of ADHD and other chronic diseases, her work provides the data necessary for more accurate risk prediction and personalised treatment strategies. This research is a cornerstone for the future of mental health technology in Estonia.

FemTech and the New Standard of Hormonal Wellness

One of the most rapidly growing segments within the Estonian ecosystem is FemTech, where leaders are addressing unmet needs in women’s health through innovative hardware and software solutions.

Kerli Luks: Pioneering Real-Time Hormone Monitoring

Kerli Luks, the founder and CEO of Muun Health, has identified a critical underserved area in women's health: continuous, non-invasive hormone monitoring. Founded in 2023, Muun Health has developed a wearable biosensor that tracks female sex hormones multiple times per day, providing real-time data to a mobile application.

Luks’s medical background and ten years of experience in clinical settings informed her vision of a "glucose monitor for hormones". This technology is particularly relevant for fertility tracking and the management of hormonal imbalances that affect overall well-being. By securing €545K in pre-seed funding from strategic partners like Greiner Innoventures, Luks is positioning Muun Health as a global leader in hormone health technology, focusing on clinical validation and the expansion of the company’s IP portfolio.

Agne Velthut-Meikas: Advancing Ovarian Research and Fertility Assessment

Professor Agne Velthut-Meikas of TalTech has been recognized for her extensive research into female fertility and ovarian function. Awarded the title of Young Researcher of the Year, Velthut-Meikas leads studies that examine the effects of digital tools on the entrepreneurial health ecosystem and the biological mechanisms of human ovaries.

Her research group’s work on fertility assessment is crucial for developing new diagnostics that can identify reproductive health disorders earlier and more accurately. This academic work is tightly integrated with the clinical and startup community, providing the fundamental science required for products that aim to increase healthy life years and improve reproductive outcomes.

Leader	Specialty	Key Research or Initiative	Impact on Sector
Kelli Lehto	Neurogenomics	ERC project on adult ADHD.	Improving mental health diagnostics via multi-omics.
Kerli Luks	FemTech Hardware	Continuous hormone monitoring biosensor.	Empowering women with real-time hormonal data.
Agne Velthut-Meikas	Reproductive Bio	Ovarian function and fertility assessment.	Scientific foundation for infertility diagnostics.
Anna-Liisa Parts	Clinical Trials	AI-automated trial monitoring.	Reducing time-to-market for life-saving drugs.
Jürgen Lorenz	Clinical Trials	CEO of Menken Trials.	Driving international adoption of trial automation.

The Infrastructure of Personalisation: Digital Health and Primary Care

The future of Estonian healthtech is defined by the move from descriptive analytics to predictive and prescriptive decision support, a transition enabled by leaders in digital health architecture.

Peeter Ross: Educating the Next Generation of Digital Clinicians

Professor Peeter Ross, a radiologist and Professor of e-Health at TalTech, is a key figure in the formal education and research programs that sustain the Estonian health ecosystem. Ross is responsible for the Digital Health master’s and PhD programs, ensuring that clinicians and engineers have a shared language for innovation.

His research projects, such as NORDeHEALTH, focus on providing patients with online access to their electronic health records and increasing self-management in healthcare. By studying the implementation and adoption of personal e-health services across the Nordic countries, Ross provides the guidelines and frameworks required for successful health technology integration. His work in digital literacy for physicians and nurses ensures that the workforce is prepared for the transition to a more data-driven healthcare system.

Ain Aaviksoo: Bridging Policy, Business, and Clinical Practice

Dr. Ain Aaviksoo, partner and head of development at the HeBA clinic, has a unique perspective shaped by his experience as the Deputy Secretary General for Innovation at the Ministry of Social Affairs and the head of the Praxis think tank. On the advisory board of the Connected Health Cluster, Aaviksoo represents the business perspective, helping startups navigate the complexities of international health innovation.

Aaviksoo’s influence is seen in his work with Guardtime, where he advises on health data security, and his leadership in clinics that integrate digital health solutions into primary care. He is a vocal advocate for the use of digital health to bridge the "implementation gap," ensuring that new technologies are not just developed but successfully adopted by healthcare providers and patients alike.

The Convergence of Health and Social Impact

The Estonian startup ecosystem is increasingly focused on "Impact" categories, where health and well-being are prioritised as much as economic growth.

Katrina Laks: Community Leadership in Headache Management

Katrina Laks, CEO and co-founder of Migrevention, is a leader in the development of evidence-based digital therapeutics for chronic conditions like migraines. Migrevention functions as a digital headache clinic, providing patients with tools to manage their symptoms and reducing the need for pharmacological intervention.

Beyond her work at Migrevention, Laks serves as the Community Lead for Health Founders Estonia, where she moderates discussions on the future of personalized medicine and ensures that the healthtech community remains cohesive. Her dual role as an entrepreneur and community leader is essential for fostering the "co-creation" culture that defines the Estonian ecosystem.

Mihkel Tedremaa: Continuous Body Temperature Monitoring

Mihkel Tedremaa, co-founder of TempID, leads a medtech company that provides reliable and reusable solutions for continuous body temperature monitoring. This technology is vital for both home and professional care, particularly in monitoring post-operative patients and the elderly.

Tedremaa’s background in engineering and product development allows TempID to offer a robust hardware solution that integrates seamlessly into digital health platforms. As healthcare shifts toward remote monitoring, the work of leaders like Tedremaa provides the necessary physical infrastructure to collect the high-fidelity data required for clinical decision support.

Synthesis: The Causal Mechanisms of Estonian Success

The collective work of these twenty leaders reveals a set of second-order trends that explain Estonia's outsized influence on the global healthtech stage.

First, the "Data Continuity" principle is paramount. By linking genomic data (Milani, Laisk) with real-time monitoring (Luks, Tedremaa) and EHR integration (Ross, Aaviksoo), Estonia creates a continuous digital narrative for each patient. This narrative allows for the development of AI tools (Veiman, Salumaa) that can predict health events before they occur, shifting the focus from cure to prevention.

Second, the "Regulatory Partnership" model is a key differentiator. The proximity between government policy (Särav-Tammus), academic research (Esko, Ross), and startup acceleration (Mölder, Saare) creates a feedback loop that accelerates innovation. This model reduces the risk for investors and allows founders to focus on clinical validation rather than bureaucratic survival.

Third, the "Exportable Infrastructure" focus ensures global scalability. Whether it is a remote diagnostic platform (Narusk), a clinical trial tool (Parts), or a nanofiber production method (Martens), Estonian leaders are building solutions designed for the world's most complex and valuable markets. This focus on global impact ensures that Estonian medtech is not a local anomaly but a scalable model for the future of European medicine.

The casual relationship between Estonia's digital identity and healthtech success is most evident in the work of Certific and SpeakTX. Without a secure, nationwide digital identity, remote diagnostics and verified digital therapeutics would be impossible at scale. These twenty leaders are not just building companies; they are leveraging a unique national infrastructure to define a new paradigm of human health that is personalised, proactive, and radically accessible.

Leader	Strategic Role	Future Focus Area
Lili Milani	Scientific Lead	Implementation of pharmacogenomics at the national scale.
Peeter Padrik	Clinical Innovator	Personalized cancer prevention via PRS.
Olesja Bondarenko	DeepTech Founder	Nanotechnology solutions for AMR and chronic wounds.
Sandra Särav-Tammus	Policy Architect	Regulatory environment for healthtech unicorns.
Erki Mölder	Ecosystem Builder	Acceleration of 100 science-based health companies.

The analysis suggests that by 2035, the integration of these technologies, genomics, real-time biosensing, and AI-driven clinical support, will result in a healthcare system that is essentially invisible, operating in the background of daily life to ensure longevity and prevent disease.

The twenty individuals identified in this report are the primary agents of this change, ensuring that Estonia remains the epicenter of the global healthtech renaissance.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech